Ophthalmic Patents (Class 514/912)
-
Patent number: 7654728Abstract: A system and method for generating an oxygen enriched aqueous solution for therapeutic application includes a diffuser comprising a first diffusing member having a surface incorporating surface disturbances, and a second diffusing member positioned relative to the first diffusing member to form a channel through which an aqueous solution and oxygen gas may flow. A reservoir containing the aqueous solution is connected to a pump that draws the aqueous solution from the reservoir and inputs the aqueous solution into the diffuser. The aqueous solution is moved through the channel relative to the surface disturbances to create cavitation in the aqueous solution to diffuse the oxygen gas into the aqueous solution to produce an oxygen enriched aqueous solution.Type: GrantFiled: June 25, 2004Date of Patent: February 2, 2010Assignee: Revalesio CorporationInventors: Anthony B. Wood, Gregory J. Archambeau, Richard A. Klena
-
Patent number: 7625864Abstract: The present invention provides a method for treating and/or preventing damage to a retina or optic nerve in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in combination with mannose, a mannose derivative and/or inosine.Type: GrantFiled: June 30, 2008Date of Patent: December 1, 2009Assignee: Children's Medical Center CorporationInventors: Larry I. Benowitz, Yuqin Yin
-
Patent number: 7479481Abstract: Compositions and methods for treating ocular diseases and disorders are provided. The composition can contain at least one lantibiotic, which can be administered topically by injection, systemically, or by other appropriate means. The methods provided include the administration of a therapeutically effective amount of a formulation containing at least one lantibiotic to the appropriate section of the eye.Type: GrantFiled: May 6, 2005Date of Patent: January 20, 2009Assignee: Molichem Medicines, Inc.Inventor: Luis Molina
-
Patent number: 7432307Abstract: Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies.Type: GrantFiled: November 4, 2005Date of Patent: October 7, 2008Assignee: Sirion Therapeutics, Inc.Inventors: Nathan L. Mata, Kenneth Widder, Jay Lichter
-
Patent number: 7429483Abstract: The nerve growth factor (NGF) is used for the storage of corneas in culture, for the production and the storage in vitro of single cell populations of the corneal morphological and functional unit (i.e. epithelium, stroma/keratocytes and endothelium) and of the conjunctival epithelium, and for the production and the storage of corneal and conjunctival tissues, in particular for transplantation purposes. The NGF is also proposed for use in the therapy and/or the prophylaxis of diseases of the corneal surface, wherein a lack of integrity of the corneal and conjunctival morphological and functional unit occurs, in particular for pathologies having a dystrophic or neurodystrophic basis, both congenital and acquired.Type: GrantFiled: January 8, 2003Date of Patent: September 30, 2008Assignee: Anabasis S.R.L.Inventor: Alessandro Lambiase
-
Patent number: 7429602Abstract: Treating allergic conjunctivitis by administered aqueous solutions containing epinastine, optionally in the form of its racemate or its enantiomers and optionally, in the form of the pharmacologically acceptable acid addition salts thereof, to the conjunctiva.Type: GrantFiled: September 27, 2007Date of Patent: September 30, 2008Assignee: Boehringer Ingelheim Pharma GmbH & Co. KgInventors: Volker Trach, Gerold Duschler
-
Patent number: 7413759Abstract: Methods for enhancing cognitive ability in infants are shown. The methods comprise feeding infants baby-food compositions containing docosahexaenoic acid (DHA) in an amount of at least about 0.5 mg per gram of the composition. Infants fed a composition containing DHA from an age of about 6 months to about one year exhibit improved problem solving ability compared to infants fed a composition containing DHA in an amount less than about 5 mg per 100 grams total composition over the same period. The source of the DHA can be DHA-enriched coagulated egg yolk solids present in an amount of from about 5% to about 25% (grams/100 grams). Also shown are methods of making the DHA-enriched baby-food compositions, and methods of providing the compositions to a consumer.Type: GrantFiled: October 21, 2004Date of Patent: August 19, 2008Assignee: Beech-Nut Nutrition CorporationInventors: Eileen E. Birch, Mary Beth Cool, Robert A. Harvey, Dennis R. Hoffman, Terry L. Rocklin, Virginia A. San Fanandre, Gerald E. Shaul, Richard C. Theuer
-
Patent number: 7364723Abstract: A highly safe liquid preparation for contact lenses which contains 0.3 to 50 ppm of a polyamine having recurring units of the formula (I): wherein n is 0 or 1, and which has a high antibacterial effect even at low concentrations.Type: GrantFiled: September 20, 1999Date of Patent: April 29, 2008Assignee: Menicon Co., Ltd.Inventors: Kazuhiko Nakada, Chikako Nakamura, Tatsuya Hayashi
-
Patent number: 7344725Abstract: The use of inorganic nanoparticles to stabilize aqueous hydrogen peroxide solutions is described. The preferred nanoparticles are formed from clays. The use of nanoparticles formed from synthetic smectite clays is particularly preferred. The stabilized hydrogen peroxide solutions may be utilized for various purposes, but are particularly useful as contact lens disinfecting solutions.Type: GrantFiled: November 16, 2004Date of Patent: March 18, 2008Assignee: Alcon, Inc.Inventors: Howard Allen Ketelson, Nathaniel D. McQueen
-
Patent number: 7335682Abstract: A pharmaceutical composition for the treatment of immune-related diseases of ocular surface and the anterior segment of the eye. More specifically, the invention relates to a composition comprising tacrolimus in a pharmaceutically acceptable formulation, particularly a suitable local treatment formulation, such as eye drops and ointments. Also disclosed is a method for the treatment of immune-response related ocular diseases of the anterior segment of the eye and the eye surface, wherein the method comprises administering to a patient in need thereof the pharmaceutical composition of the present invention. The method of the present invention preferably further comprises administering to the patient an immunosuppressant in addition to tacrolimus.Type: GrantFiled: May 12, 2003Date of Patent: February 26, 2008Assignee: The Zhongshan Opthalmic CenterInventors: Jiaqi Chen, Yongmin Liu
-
Patent number: 7335803Abstract: Methods and compositions for the treatment of pain and intraocular pressure. Particularly disclosed are new compositions for the treatment of chronic pain, glaucoma and methods for their use.Type: GrantFiled: October 19, 2001Date of Patent: February 26, 2008Assignee: Allergan, Inc.Inventors: Ken Chow, Daniel W. Gil, Wenkui Ken Fang, Michael E. Garst, Larry A. Wheeler
-
Patent number: 7320786Abstract: This invention discloses methods, kits, and instructions to treat neovasculature diseases of the eye through the administration of a targeted photosensitizing agent and subsequent exposure to light of specific wavelength sufficient to photoactivate photosensitizing agent. The photosensitizing agent is bound to a composition that mediates site specific delivery to a neovasculature target tissue of a therapeutically effective amount of a photosensitizing agent that is activated by a relatively low fluence rate of light over a prolonged period of time. Diseases treatable under this invention, include: diabetic retinopathy; macular degeneration; and malignant uveal melanomas.Type: GrantFiled: December 7, 2005Date of Patent: January 22, 2008Assignee: Light Sciences Oncology, Inc.Inventor: James C. Chen
-
Patent number: 7321000Abstract: An ophthalmic pharmaceutical composition containing acetylcysteine as the active ingredient having a mucolitic action, suitable for administration in eyedrops, where N-acetyl-cysteine is neutralised with base DEAE-dextrane in order to reach pH levels preferably between 6.0 and 7.5, and having a physiologically acceptable osmolarity less than 320 mOsm/kg. The presence of a neutralising agent for N-acetyl-cysteine that does not negatively affect the composition osmolarity allows the formulation to be isotonic or even hypotonic, thus avoiding the irritative and potentially damaging effects of previous ophthalmic products containing N-acetyl-cysteine.Type: GrantFiled: July 22, 2002Date of Patent: January 22, 2008Assignee: Farmigea S.p.A.Inventors: Enrico Boldrini, Marco Fabrizio Saettone, Patrizia Chetoni, Susi Burgalassi, Boris Giannaccini
-
Patent number: 7306802Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity.Type: GrantFiled: June 4, 2007Date of Patent: December 11, 2007Assignee: Alcon, Inc.Inventors: Masood A. Chowhan, Huagang Chen
-
Patent number: 7297679Abstract: A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein.Type: GrantFiled: July 13, 2005Date of Patent: November 20, 2007Assignee: Allergan, Inc.Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
-
Patent number: 7288520Abstract: A composition is disclosed herein comprising from about 0.001% to about 0.Type: GrantFiled: October 19, 2005Date of Patent: October 30, 2007Assignee: Allergan, Inc.Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
-
Patent number: 7276476Abstract: A composition comprising from 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil selected from the group consisting of anise oil, clove oil, cassia oil, cinnamon oil, and combinations thereof, wherein said composition is an ophthalmically acceptable emulsion is disclosed herein.Type: GrantFiled: July 13, 2005Date of Patent: October 2, 2007Assignee: Allergan, Inc.Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
-
Patent number: 7268137Abstract: A method for treating a subject suffering from epiretinal membrane formation or retinal detachment due to epiretinal membrane formation is disclosed. The method comprises administering a compound of the formula: wherein n is 0 to 2, R is H or lower alkyl; X is imino, oxa, or thia; Y is aryl; and Z is unsubstituted or substituted pyridyl, an N-oxide thereof, wherein 1 or more N atoms carry an oxygen atom, or a salt thereof.Type: GrantFiled: November 7, 2003Date of Patent: September 11, 2007Inventor: Peter A. Campochiaro
-
Patent number: 7267830Abstract: The present invention provides improved dietary supplements and methods for inhibiting the progression of macular degeneration and promoting healthy vision. The dietary supplements of the invention contain cobeadlets comprising vitamin E and carotenoids in the form of Vitamin A, lutein and/or zeaxanthing. The dietary supplements of the invention further contain Vitamin C, copper and zinc and may also contain such ingredients as rosemary, DHA, other vitamins and minerals.Type: GrantFiled: December 14, 2004Date of Patent: September 11, 2007Assignee: Alcon, Inc.Inventor: John C. Lang
-
Patent number: 7265098Abstract: The present invention relates to improved methods for delivering bioadhesive, bioresorbable, anti-adhesion compositions. Antiadhesion compositions can be made of intermacromolecular complexes of carboxyl-containing polysaccharides, polyethers, polyacids, polyalkylene oxides, multivalent cations and/or polycations. The polymers are associated with each other, and are then used as fluids, gels or foams. By providing a product bag, the compositions can be delivered as gels or as sprays. By dissolving propellant gases in the compositions, the materials can be delivered as foams, which have decreased density, and therefore can adhere to surfaces that previously have been difficult to coat with antiadhesion gels. Delivery systems can also provide mechanisms for expelling more product, and for directing the flow of materials leaving the delivery system. Bioresorbable, bioadhesive, anti-adhesion, and/or hemostatic compositions are useful in surgery to prevent the formation and reformation of post-surgical adhesions.Type: GrantFiled: February 20, 2003Date of Patent: September 4, 2007Assignee: Fziomed, Inc.Inventors: Mark E. Miller, Stephanie M. Cortese, Herbert E. Schwartz, William G. Oppelt
-
Patent number: 7265117Abstract: Topical solution compositions of brimonidine tartrate are disclosed. The solution compositions lack an oxidative preservative.Type: GrantFiled: May 5, 2005Date of Patent: September 4, 2007Assignee: Alcon, Inc.Inventors: Ramon L. Espino, Haresh G. Bhagat
-
Patent number: 7247623Abstract: A method and preparation for reducing dry eye symptoms and promoting tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the eyes of the subject a non-drying antihistamine compound, such as epinastine hydrochloride, in an amount effective to reduce dry eye symptoms and stimulate tear fluid secretion. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the compound include topical administration via a liquid, gel, cream, or as part of a contact lens or a continuous or selective release device; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.Type: GrantFiled: August 10, 2006Date of Patent: July 24, 2007Assignee: Inspire Pharmaceuticals, Inc.Inventors: Benjamin R. Yerxa, Jason L. Vittitow, John C. Ice, Jr.
-
Patent number: 7235535Abstract: A method and preparation for enhancing drainage of lacrimal system in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5?-triphosphate (UTP), dinucleotides, cytidine 5?-triphosphate (CTP), adenosine 5?-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.Type: GrantFiled: April 25, 2005Date of Patent: June 26, 2007Assignee: Inspire Pharmaceuticals, Inc.Inventors: Benjamin R. Yerxa, Karla M. Jacobus, William Pendergast, Janet L. Rideout
-
Patent number: 7235556Abstract: Fused pyridazine derivatives are useful for treating dry eye disorders and other disorders requiring the wetting of the eye.Type: GrantFiled: April 14, 2004Date of Patent: June 26, 2007Assignee: Alcon, Inc.Inventors: Najam A. Sharif, Mark R. Hellberg
-
Patent number: 7232568Abstract: The present invention comprises and utilizes methods and compositions for treating hyperimmune reactions in the eye. Compositions comprising antibodies to gamma interferon alone and in combination with other drugs are described. Also disclosed in the invention are methods of applying a composition comprising interferon gamma antibodies topically to the eye to treat hyperimmune reactions, such as transplant rejection, autoimmune diseases of the eye, and ocular disorders incidental to or connected with autoimmune diseases.Type: GrantFiled: February 21, 2003Date of Patent: June 19, 2007Assignee: Advanced Biotherapy, Inc.Inventors: Boris Skurkovich, Simon Skurkovich
-
Patent number: 7230032Abstract: Glutamate causes migration and proliferation of retinal pigment epithelium and/or glial cells, and glutamate antagonists can prevent, treat or reduce retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreoretinopathy. Avoidance or management of proliferative vitreoretinopathy can be achieved by administering to the patient a compound capable of reducing glutamate-induced retinal cell migration in a concentration effective to reduce such migration.Type: GrantFiled: May 12, 2003Date of Patent: June 12, 2007Assignee: Allergan, Inc.Inventor: Evan B. Dreyer
-
Patent number: 7223737Abstract: The topical use of glycosides for the treatment of dry eye disorders is disclosed.Type: GrantFiled: August 10, 2005Date of Patent: May 29, 2007Assignee: Alcon, Inc.Inventors: Victor Ke, legal representative, Tai-Lee Ke, deceased
-
Patent number: 7220780Abstract: The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors.Type: GrantFiled: May 30, 2001Date of Patent: May 22, 2007Assignee: Guilford Pharmaceuticals Inc.Inventors: Barbara S. Slusher, Krystyna Wozniak
-
Patent number: 7214379Abstract: Marigold oleoresin having a low viscosity and a high lutein content which can be filled in soft capsules can be obtained according to the method of the present invention, which is characterized by combining a step of subjecting oleoresin to supercritical fluid extraction and a step of dissolving oleoresin in a ketone solvent, cooling the solution and removing the ingredient which precipitated in solution.Type: GrantFiled: September 22, 2003Date of Patent: May 8, 2007Assignee: Riken Vitamin Co., Ltd.Inventors: Shin Sadano, Kazuhiro Fujiwara, Koichi Harada
-
Patent number: 7202209Abstract: A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein.Type: GrantFiled: July 13, 2005Date of Patent: April 10, 2007Assignee: Allergan, Inc.Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
-
Patent number: 7169767Abstract: The present invention is directed to ophthalmic compositions containing a gelling amount of a combination of galactomannan polysaccharides and borates. The compositions gel or partially gel upon administration to the eye. The present invention also discloses methods of topical ophthalmic administration of the compositions to the eye.Type: GrantFiled: November 24, 2004Date of Patent: January 30, 2007Assignee: Alcon Manufacturing, Ltd.Inventor: Bahram Asgharian
-
Patent number: 7141266Abstract: Baby-food compositions that enhance visual acuity upon feeding to an infant are shown. The compositions contain docosahexaenoic acid (DHA) in an amount of at least about 0.5 mg per gram of the composition. The source of the DHA can be from DHA-enriched coagulated egg yolk solids present in an amount of from about 5% to about 25% (grams/100 grams). The compositions have an organoleptically acceptable smooth texture as a result of contain an acidulant or as a result of being processed by a microcutter. Also shown are methods for enhancing visual acuity in infants and methods of providing the compositions to a consumer.Type: GrantFiled: November 6, 2003Date of Patent: November 28, 2006Assignee: Beech-Nut Nutrition CorporationInventors: Richard C Theuer, Eileen E Birch, Dennis R Hoffman, Gerald E Shaul, Terry L Rocklin, Mary B Cool, Virginia A San Fanandre, Robert A Harvey
-
Patent number: 7129272Abstract: Disclosed is a method for treatment of a subject having a disease or condition associated with apoptosis, which comprises administering to the subject an effective amount of a 15-keto-prostaglandin compound represented by the following formula (I):Type: GrantFiled: March 26, 2001Date of Patent: October 31, 2006Assignee: Sucampo AGInventors: Ryuji Ueno, Yukihiko Mashima
-
Patent number: 7122518Abstract: A method is provided for preventing or reducing the adverse effects of photodynamic therapy such as collateral damage by regulating the localized phototoxicity of an effector photosensitizer molecule. During photodynamic therapy, the activity of the effector photosensitizer molecule in neighboring tissues of the tissue targeted for destruction is quenched by a quenching photosensitizer molecule.Type: GrantFiled: November 25, 2003Date of Patent: October 17, 2006Assignee: New York UniversityInventor: Gad Lavie
-
Patent number: 7115263Abstract: The present invention comprises and utilizes methods and compositions for treating hyperimmune reactions in the eye. Compositions comprising antibodies to gamma interferon alone and in combination with other drugs are described. Also disclosed in the invention are methods of applying a composition comprising interferon gamma antibodies topically to the eye to treat hyperimmune reactions, such as transplant rejection, uveitis, autoimmune diseases of the eye, and ocular disorders incidental to or connected with autoimmune diseases.Type: GrantFiled: February 28, 2005Date of Patent: October 3, 2006Assignee: Advanced Biotherapy, Inc.Inventors: Boris Skurkovich, Simon Skurkovich
-
Patent number: 7115667Abstract: An ophthalmic fluid containing at least one triglyceride, diglyceride, or monoglyceride which is chemically similar or compatible with compounds found naturally in the lipid layer of the tear film of an ocular substrate. Preferably the glycerides are derived from a fatty acid containing at least one unsaturated bond in a cis-configuration in the fatty acid residue. The ophthalmic fluid is arranged in use to provide a protective film across a tear film of an ocular substrate. Furthermore, the ophthalmic fluid is also arranged in use to provide a protective film intermediate a lipid layer of the tear film of the ocular substrate and a contact lens.Type: GrantFiled: February 18, 2004Date of Patent: October 3, 2006Assignee: Planned Products Pty Ltd.Inventor: Anthony William Sly
-
Patent number: 7112588Abstract: Proteasome inhibitors are useful for treating dry eye disorders and other disorders requiring the wetting of the eye.Type: GrantFiled: March 24, 2004Date of Patent: September 26, 2006Assignee: Alcon, Inc.Inventors: Peter G. Klimko, Mark R. Hellberg
-
Patent number: 7109187Abstract: The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods.Type: GrantFiled: February 12, 2001Date of Patent: September 19, 2006Assignee: The Children's Medical Center CorporationInventors: Robert John D'Amato, Moses Judah Folkman
-
Patent number: 7105512Abstract: The present invention provides an ophthalmic aqueous pharmaceutical preparation, which is excellent in anti-inflammatory effect, which is less stimulative and which has high safety and excellent storage stability. The ophthalmic aqueous pharmaceutical preparation comprises meloxicam and trometamol.Type: GrantFiled: May 24, 2002Date of Patent: September 12, 2006Assignee: Wakamoto Pharmaceutical Co., Ltd.Inventors: Daisuke Morizono, Hidekazu Suzuki, Masanobu Takeuchi, Kenji Naito
-
Patent number: 7087249Abstract: The invention relates to the use of one or more antimicrobial metals preferably selected from silver, gold, platinum, and palladium but most preferably silver, formed with atomic disorder, and preferably in a nanocrystalline form, for reducing inflammation or infection of the mucosal membrane. The antimicrobial metal may be formulated as, or used in the form of, a nanocrystalline coating of one or more antimicrobial or noble metals, a nanocrystalline powder of one or more antimicrobial or noble metals, or a liquid or solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial or noble metals.Type: GrantFiled: April 23, 2002Date of Patent: August 8, 2006Assignee: Nucryst Pharmaceuticals Corp.Inventors: Robert Edward Burrell, Antony George Naylor, Peter Howard Moxham
-
Patent number: 7084128Abstract: The present invention is directed to a method of reducing intraocular pressure. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a purinerginic receptor ligand, which is a mononucleoside polyphosphate or dinucleoside polyphosphate defined by general Formula I. The method of the present invention is useful in the treatment or prevention of ocular hypertension, such as glaucoma, including primary and secondary glaucoma. The method can be used alone to reduce intraocular pressure. The method can also be used in conjunction with other therapeutic agents or adjunctive therapy commonly used to treat glaucoma to enhance the therapeutic effect of reducing the intraocular pressure.Type: GrantFiled: January 15, 2003Date of Patent: August 1, 2006Assignee: Inspire Pharmaceuticals, Inc.Inventors: Benjamin R. Yerxa, Robert Plourde, Jr., Edward G. Brown, Ward M. Peterson
-
Patent number: 7081482Abstract: The invention is directed to the use of ?-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina.Type: GrantFiled: November 29, 2000Date of Patent: July 25, 2006Assignee: Alcon, Inc.Inventors: Robert J. Collier, Jr., Louis Desantis, Jr., Michael A. Kapin
-
Patent number: 7067547Abstract: The present invention relates to contact lens solutions employing imidazole as an additive. Lenses treated with these solutions have improved resistance to protein and other polymeric depositions. The addition of imidazole to the solutions decreases the denaturalization of proteins during the cleaning cycles, and coats treated lenses to decrease the number of active binding sites.Type: GrantFiled: November 4, 2000Date of Patent: June 27, 2006Assignee: FXS Ventures, LLCInventor: Francis X. Smith
-
Patent number: 7064141Abstract: To provide a pharmaceutical composition for preventing, treating or development-inhibiting simple retinopathy or preproliferative retinopathy, comprising a compound having angiotensin II antagonistic activity, or a salt thereof.Type: GrantFiled: April 27, 2000Date of Patent: June 20, 2006Assignee: Takeda Pharmaceutical Company LimitedInventors: Shizue Nakagawa, Yasutaka Nagisa, Hitoshi Ikeda
-
Patent number: 7060695Abstract: An improved method to treat conditions of the eye characterized by ocular neovascularization is provided in which patients are given and initial photodynamic therapy (PDT) treatment to destroy the neovasculature, and then are re-evaluated at least twice during the following 6 months, and retreated as necessary. Preferably, three retreatments are provided.Type: GrantFiled: February 6, 2002Date of Patent: June 13, 2006Assignees: QLT, Inc., Novartis AGInventors: H. Andrew Strong, Mohammad Azab, Troy Albert Reaves, Jr.
-
Patent number: 7049340Abstract: The invention concerns a neuroprotective and retinoprotective medicine, whereof the active principle is selected among a group of compounds consisting of ramipril, ramiprilat or any other ramiprilat derivative capable of releasing it in the organism whereto it is administered. Said medicine is used for prevention, or even for improving visual acuity and visual field in normal subjects, as well as for treating ophthalmologic pathologies involving a vascular factor, in particular glaucomatous neuropathy, degenerative choriopathy of strong myopia, age-related maculopathy, serous central chorioretinopathy, hereditary dystrophy of the retina and retinal venous occlusions. It almost invariably improves the visual function (acuity and visual field).Type: GrantFiled: June 16, 2000Date of Patent: May 23, 2006Inventor: Raouf Rekik
-
Patent number: 7045121Abstract: Ophthalmic compositions include an ophthalmically acceptable carrier component, for example, an aqueous-based carrier, and a plurality of polyanionic component portions having different molecular weights. In one embodiment, the polyanionic component includes a first polyanionic component portion having a first molecular weight; and a second polyanionic component portion having a different second molecular weight. Each of the first and second polyanionic component portions is present in an amount effective to provide lubrication to an eye when the composition is administered to an eye. Methods of making and using such compositions are also disclosed.Type: GrantFiled: December 14, 2001Date of Patent: May 16, 2006Assignee: Allergan, Inc.Inventors: James N. Chang, Teresa H. Kuan
-
Patent number: 7037943Abstract: A method for treating or preventing retinal pathology or injury. The method locates and secures a retinal stimulating substance in the eye between the internal limiting membrane and the retina, which is the target site for the substance. The substance may be an implant that provides electrical stimulation to adjacent ganglion and neurofiber cells. Alternatively, the substance may be a pharmaceutical substance to stimulate the retina. In addition to providing direct contact of the substance with its target, the method obviates the need for artificial structures such as tacks or adhesives which may cause retinal bleeding or traction.Type: GrantFiled: April 10, 2001Date of Patent: May 2, 2006Assignee: Optobionics CorporationInventor: Gholam Peyman
-
Patent number: 7026359Abstract: The invention relates to the utilization of a highly fluorinated oligomeric alkane as a therapeutic agent in ophthalmology, the alkane having the general formula [—RF(CH2)nCR1—CR2—]x, wherein RF is a linear or branched perfluorinated alkyl chain C2F5 to C12F23, R1 and R2 are independently selected from the group consisting of H, CH3, C2H5 and C3H7, n is selected from the numbers 0, 1 and 2, and x is a number between 2 and 6, with a molar mass of at least 750. According to the invention, a pharmacological agent is provided that is used in ophthalmology and that causes little or no damage to the retina even when used over a long period.Type: GrantFiled: April 27, 2000Date of Patent: April 11, 2006Assignee: Bausch & Lomb IncorporatedInventors: Udo Gross, Dirk-Henning Menz, Erhard Kemnitz, Hans Hoerauf, Karin Kobuch
-
Patent number: 7008960Abstract: Methods and preparatons for treating disorders of the eye and/or causing posterior vitreous disconnection or disinsertion. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) a non-steroidal anti-inflamatory agents, d) antmetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, thymidine, thimitadine, uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.Type: GrantFiled: August 9, 2002Date of Patent: March 7, 2006Assignee: Vitreo-Retinal Technologies, Inc.Inventor: David Castillejos